par Mathieu, Chantal;Overbergh, Lut;Badenhoop, Klaus;Bingley, Penelope P.J.;Dayan, Colin C.M.;Demengeot, Jocelyne;Dotta, Francesco;Eizirik, Decio L. 
;Lenzen, Sigurd;Marchetti, Piero;Peakman, Mark;Roep, Bart;Todd, John;Rottiers, Pieter;Megit, Stephen
Référence European Endocrinology, 10, 2, page (100-105)
Publication Publié, 2014
;Lenzen, Sigurd;Marchetti, Piero;Peakman, Mark;Roep, Bart;Todd, John;Rottiers, Pieter;Megit, StephenRéférence European Endocrinology, 10, 2, page (100-105)
Publication Publié, 2014
Article révisé par les pairs
| Résumé : | NAIMIT (acronym for Natural Immune Modulation for Intervention in Type 1 Diabetes) is a large-scale collaborative programme of the 7th framework from the European Commission. The aim of the consortium is to bring together a group of leading European researchers spanning the field from genetics, through pancreatic beta-cell, dendritic cells and T-cell biology, towards clinical interventions. The ultimate goal is to develop novel and personalised interventional therapies in recent-onset type 1 diabetic patients, with minimal immune system interference, leading to beta-cell protection and restoration, based on a solid understanding of the disease pathogenesis, enabling experimental findings to be adopted for clinical applications. |
